ADC for Lung Cancer Approved Free

The FDA granted accelerated approval to the antibody–drug conjugate (ADC) telisotuzumab vedotin (Emrelis; AbbVie), which targets the receptor tyrosine kinase c-Met, for patients with locally advanced or metastatic, non-squamous non–small cell lung cancer (NSCLC). The approval is backed by results from the phase II, open-label LUMINOSITY study, which included 84 patients with the disease and high c-Met protein overexpression who had already tried systemic therapy. Thirty-five percent of patients achieved an objective response, the median duration of which was 7.2 months. Telisotuzumab vedotin is currently under investigation in the phase III TeliMET NSCLC-01 trial in patients with the same indication.